Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.
Vet Parasitol
; 276: 108976, 2019 Dec.
Article
en En
| MEDLINE
| ID: mdl-31739256
ABSTRACT
Cutaneous leishmaniosis (CL) is a parasitic disease in animals and human with no satisfactory treatments and vaccination. Rapamycin is a potent inhibitor of mammalian target of rapamycin (mTOR) with various applications. Here, the effect of rapamycin alone or in combination with two other drugs, namely amphotericin B (AmB) and glucantime, was investigated against Leishmania tropica infection. In vitro viability and electron microscopy evaluation of the parasites showed detrimental changes in their appearance and viability. Treatment with clinically relevant dose of rapamycin (10.2⯵g/dose) is able to control the parasite load in BALB/c mice infected with L. tropica. Furthermore, the cytokine profiles showed significant polarization towards Th1 immune response. Surprisingly, combination therapy with either AmB or glucantime was not efficient. Rapamycin is showed an effective alternative therapy against leishmaniosis caused by L. tropica.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leishmania tropica
/
Leishmaniasis Cutánea
/
Sirolimus
/
Antiprotozoarios
Tipo de estudio:
Clinical_trials
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Vet Parasitol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Irán